GC
TPTX

Guggenheim Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Guggenheim Capital’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,082
Closed -$1.66M – 2093
2022
Q2 		$1.66M Buy
22,082
+9,775
+79% +$434K 0.01% 973
2022
Q1 		$330K Buy
12,307
+504
+4% +$16.9K ﹤0.01% 1833
2021
Q4 		$563K Buy
11,803
+1,015
+9% +$45.4K ﹤0.01% 1642
2021
Q3 		$717K Buy
10,788
+1,505
+16% +$107K ﹤0.01% 1586
2021
Q2 		$724K Buy
9,283
+1,217
+15% +$89.9K ﹤0.01% 1655
2021
Q1 		$763K Buy
8,066
+3,846
+91% +$457K 0.01% 1521
2020
Q4 		$514K Buy
+4,220
New +$462K ﹤0.01% 1631

Guggenheim Capital's TPTX Position: Q3 2022 in Review

Guggenheim Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 22,082 shares — an estimated $1.66M sold.

Guggenheim Capital first reported a position in TPTX in Q4 2020 and held it in 7 quarters. The position peaked at $1.66M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Guggenheim Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Guggenheim Capital sold 22,082 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.66M.
  • Guggenheim Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Guggenheim Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.66M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.